ADVIL LIQUI-GELS (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1995.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
ADVIL LIQUI-GELS is an oral ibuprofen capsule, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase to reduce pain, inflammation, and fever. It is indicated for temporary relief of minor aches and pains due to headache, muscular aches, backache, minor arthritis pain, menstrual cramps, and the common cold. The liqui-gel formulation enables rapid absorption and faster onset of action compared to traditional tablets.
Mature OTC asset approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting focus on generic transition management and cost optimization rather than growth initiatives.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on ADVIL LIQUI-GELS at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ADVIL LIQUI-GELS offers limited career advancement given the mature, commoditized OTC landscape and approaching loss of exclusivity. Roles focus on defensive brand management, cost optimization, and generic transition rather than innovation or market expansion.